Short answer
Boston Scientific (BSX) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $5.4B (up 7.5% year over year) with net income of $906M.
Q2 2026 key financials · XBRL
- Revenue
- $5.4B
- +7.5% YoY · +4.6% QoQ
- Net income
- $906M
- +13.7% YoY · −32.4% QoQ
- Operating margin
- 21.6%
- Gross margin
- 70.7%
- EPS (diluted)
- $0.61
- +15.1% YoY · −32.2% QoQ
Source: XBRL data from the Boston Scientific (BSX) Q2 2026 10-Q on SEC EDGAR. USD.
Boston Scientific Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Headwinds: foreign exchange, tariffs, geopolitical conflicts, supply-chain disruptions, cybersecurity, labor costs
- Outlook risks: regulatory conditions, product launches, competition, reimbursement, acquisitions, procedural volumes, litigation
Risk Factors
- No material changes to 10-K risk factors disclosed
- Financial risk: $2.000 billion accelerated share repurchase reduced remaining authorization to $3.000 billion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Boston Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.